Nuvectis Pharma, Inc. (NVCT) Stock Price & Analysis
Nuvectis Pharma, Inc. (NVCT) closed at USD 18.36 on Wednesday, October 28, 2026, down 0.43% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 18.44; the Oct 28, 2026 session ranged USD 17.91–18.83 on volume of 192,736 shares. Market capitalization is $599.35M, with a 52-week range of USD 5.55–29.28 (NCM). Source: Nexqual, retrieved October 29, 2026 at 06:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NVCT.md
Key facts (NVCT)
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $916K; 1 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 35.4 (range 30–40).
- Total return with dividends: 1Y +171.2% vs S&P 500 +13.6%; 5Y +464.9% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD -0.24, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NVCT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$12.9M | -$19.2M | -$22.9M | -$19.8M | -$27.6M | -$28.9M |
| Net income | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M | -$27.8M |
| EPS (diluted) | -$3.02 | -$1.51 | -$1.43 | -$1.11 | -$1.32 | — |
| Cash + short-term investments | $5.7M | $20.0M | $19.1M | $18.5M | $31.6M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NVCT)
P/B 66.0x · Earnings yield -4.65%
Insider purchases (SEC Form 4, open-market, last ~7 months) (NVCT)
1 purchase, $916K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-30 | Mosseri Marlio Charles | 50,000 | $916K | 18.32 | Opportunistic (traded every year 2023–2025, no repeating month) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (NVCT)
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 35.4 (low 30, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | HC Wainwright & Co. | Reiterated | Buy | $39 |
| 2026-08-24 | Cantor Fitzgerald | Initiated | Overweight | |
| 2026-07-06 | Roth Capital | Target raised | Buy | $20 → $33 |
Total return (dividends reinvested) (NVCT)
| 1Y (from 2025-10-29) | 5Y (from 2022-01-31) | |
|---|---|---|
| Total return | +171.2% | +464.9% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +172.1% | +44.1% |
| Volatility (annualized) | 86.5% | 100.8% |
| Max drawdown | -36.9% (Jun 2026→Oct 2026) | -76.0% (May 2022→Dec 2024) |
NVCT earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$0.30 | −$0.26 | Miss −15.4% | -10.8% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | −$0.26 | −$0.31 | Beat +16.1% | +12.5% |
| Feb 11, 2026 | Quarter ended Dec 31, 2025 | −$0.31 | −$0.31 | In line | +0.7% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | −$0.44 | −$0.25 | Miss −76.0% | -11.2% |
| Aug 5, 2025 | — | — | — | — | -11.4% |
| May 6, 2025 | — | — | — | — | -6.5% |
| Feb 25, 2025 | — | — | — | — | -6.8% |
| Nov 5, 2024 | — | — | — | — | +29.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
NVCT recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 21, 2026 | 8-K | Other material event |
| Aug 6, 2026 | Schedule 13G | Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC: 5.1% of shares, passive 5%+ holder |
| Aug 4, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 4, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
NVCT company outlook (results filed Aug 4, 2026)
- “Bentsur concluded, “As expected following an in-licensing transaction that involves a late-stage asset with a multi-billion-dollar market potential, our main focus now is to advance ciprocopan toward a marketing application in the United States and other key territories, with NXP200 and NXP900 driving potential longer-term upside in the oncology segment.”
- “The marketing application in China for the treatment of PNH patients previously treated with anti C5 therapy is under review. o U.S. regulatory efforts underway; a pre-investigation new drug (“IND”) meeting with the Food and Drug Administration (“FDA”) followed by IND submission expected in 4Q2026. ·”
- “IND submission expected in 4Q2026. ·”
- “Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide an update by the end of this year.”
Quoted word-for-word from the SEC 8-K results press release.
NVCT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.24 | $-0.25 | $0.00 | $0 | 6 |
| Next quarter (ends Dec 2026) | $-0.25 | $-0.25 | $0.00 | $0 | 6 |
| Current fiscal year (ends Dec 2026) | $-1.04 | $-1.01 | −$0.04 | $0 | 6 |
| Next fiscal year (ends Dec 2027) | $-1.15 | $-1.01 | −$0.14 | $0 | 6 |
NVCT options: expected move
Options price a move of about ±17.8% (±$3.27) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±11.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 88.8% | ±17.8% |
| Dec 18, 2026 | 51 | 87.2% | ±25.7% |
| Jan 15, 2027 | 79 | 87.8% | ±31.9% |
| Apr 16, 2027 | 170 | 85.9% | ±44.8% |
30-day implied volatility 90.4% vs 71.1% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 06:43 UTC)
| Price | USD 18.36 |
|---|---|
| Change | ▼ 0.43% (down) |
| Previous Close | USD 18.44 |
| Open | USD 18.3 |
| Day Range | USD 17.91 – 18.83 |
| 52-Week Range | USD 5.55 – 29.28 |
| Volume | 192,736 shares |
| Market Cap | $599.35M |
| Exchange | NCM |
Technical Analysis (NVCT)
Nexqual's technical model rates NVCT "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 06:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.57 (neutral) |
| vs SMA50 | Below (USD 21.64) |
| MACD | -0.64 (negative) |
Analyst Ratings (NVCT)
Wall Street analysts rate NVCT "Buy" based on 6 analysts, with a mean price target of USD 35.4 (range USD 30–40), per Nexqual as of October 29, 2026 at 06:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 35.4 |
| High Target | USD 40 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (NVCT)
| Next Earnings Date | 2026-11-03 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.3 vs est -0.26 ▼ miss |
| 2026-03-31 | USD -0.26 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.31 vs est -0.31 ▼ miss |
| 2025-09-30 | USD -0.44 vs est -0.25 ▼ miss |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
Financials & Fundamentals (NVCT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -214.58% |
| Current Ratio | 1.68 |
| Total Cash | $22.16M |
| Total Debt | $0 |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
Financial Health Score (NVCT)
Nexqual rates Nuvectis Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 06:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $22M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$16M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -307%, ROA -124.4% (last 4 quarters, SEC) |
Ownership (NVCT)
| Insider Ownership | +34.43% |
|---|---|
| Institutional Ownership | +33.65% |
| Shares Outstanding | 32.64M |
| Float | 21.20M |
| Short % of Float | +11.06% |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
Leadership (NVCT)
Nuvectis Pharma, Inc. is led by Ron Bentsur, Co-Founder, Chairman, CEO & President, per Nexqual as of October 29, 2026 at 06:43 UTC.
| Co-Founder, Chairman, CEO & President | Ron Bentsur |
|---|---|
| Co-Founder, Executive VP, Chief Scientific & Business Officer | Enrique Poradosu |
| Vice President of Finance | Michael Carson |
Major Backers & Investors (NVCT)
Notable institutional backers of Nuvectis Pharma, Inc. include Tang Capital Management, LLC, Soleus Capital Management, L.P., Perceptive Advisors Llc, according to Nexqual as of October 29, 2026 at 06:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Tang Capital Management, LLC | 4.75% |
| Soleus Capital Management, L.P. | 3.06% |
| Perceptive Advisors Llc | 3.06% |
| Iridian Asset Management LLC | 2.43% |
| Sphera Funds Management Ltd. | 1.17% |
| Baldwin Wealth Partners LLC/MA | 1.17% |
| Fidelity | 1.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.07% |
| Vanguard Group | 2.67% |
| Geode Capital | 1.32% |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
From Nuvectis Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Manufacturing, marketing, sales, advertising, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare & Medicaid Services ("CMS") an agency within the U.S.
- We also rely on know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.
- Our ability to maintain and solidify our proprietary and intellectual property position for our current or future product candidates and technologies depends on our success in obtaining effective patent claims and enforcing those claims if granted.
- However, our current patent applications and any patent applications that we may in the future file or license from third parties may not result in the issuance of patents, and any issued patents we may obtain may not guarantee us the right to practice our technology in relation to the commercialization of our products.
Partnerships
- In May 2021, we entered into a worldwide, exclusive license agreement with the CRT Pioneer Fund ("CRT") for NXP800 and any of its derivatives (collectively, the "NXP800 Program").
- Pursuant to the License Agreement, we have an obligation to pay success-based milestones and royalties to the UoE, as follows: In addition, in connection with the License Agreement, we expect to provide the UoE with up to an additional £580,000 in research and development support over the next 18 months to conduct additional scientific research and preclinical testing for certain indications that we select in connection with the NXP900 Program.
Legal & Regulatory Risks (Item 1A, quoted)
- We may also submit marketing applications in other countries.
- The FDA or a comparable foreign regulatory authority may also impose requirements for costly post-marketing nonclinical studies or clinical trials (often called "Phase 4 trials") and post-marketing surveillance to monitor the safety or efficacy of the product.
- Adverse pricing limitations may hinder our ability to recoup our investment in one or more of our current or future product candidates, even if any such current or future product candidate we may develop obtains marketing approval.
- Risks Related to our Intellectual Property
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 91.97 | ▼ 0.23% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| PRAX | Praxis Precision Medicines, Inc | USD 285.48 | ▲ 6.69% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt